for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Linical Co., Ltd.

2183.T

Latest Trade

894.00JPY

Change

-23.00(-2.51%)

Volume

69,600

Today's Range

888.00

 - 

918.00

52 Week Range

683.00

 - 

1,029.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
917.00
Open
905.00
Volume
69,600
3M AVG Volume
2.06
Today's High
918.00
Today's Low
888.00
52 Week High
1,029.00
52 Week Low
683.00
Shares Out (MIL)
22.59
Market Cap (MIL)
22,686.58
Forward P/E
47.03
Dividend (Yield %)
1.53

Next Event

Q1 2022 Linical Co Ltd Earnings Release

Latest Developments

More

Linical: To Buy Back Up To 100 Million Yen Of Its Own Shares Through Jan 31

Linical unit to buy Accelovance for 3.47 bln yen

Linical unit sets up unit LINICAL Czech Republic s.r.o.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Linical Co., Ltd.

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Industry

Biotechnology & Drugs

Contact Info

10F, Shin-Osaka Brick Bldg

1-6-1, Miyahara

Yodogawa-ku

OSAKA-SHI, OSK

532-0003

Japan

+81.6.61502478

https://www.linical.co.jp/

Executive Leadership

Kazuhiro Hatano

President, Chief Director of Development, Representative Director

Akihiro Takahashi

Senior Managing Director, Chief Financial Officer, Chief Director of Administration

Keigo Tsujimoto

Vice President, Manager of International Business Development Office, President of Subsidiary, Director

Jun Kawai

Senior Managing Director, Deputy Chief Director of Development (Osaka), Director of 3rd Development, Chairman & President of Subsidiaries

Yoshio Kaji

Managing Director, Manager of Business Planning Office

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (JPY)

2019

25.089

2020

21.384

2021

23.910

2022(E)

19.500
Price To Earnings (TTM)
38.36
Price To Sales (TTM)
2.21
Price To Book (MRQ)
3.63
Price To Cash Flow (TTM)
23.56
Total Debt To Equity (MRQ)
83.63
LT Debt To Equity (MRQ)
62.00
Return on Investment (TTM)
5.66
Return on Equity (TTM)
3.66

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up